RxDoctor Payments Data

Sana Hasan, DO

Endocrinology, Diabetes & Metabolism · Cleveland, OHNPI 1003071416

Payments from drug & device makers

$1,140in general payments, 2019–2025

Across 36 payments — averaging $31.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$316
  • Novo Nordisk$307
  • Lilly USA, LLC$84
  • Medtronic$74
  • Corcept Therapeutics$63
  • Ascendis Pharma Endocrinology Inc$60
  • plus $237 from 9 others

What the payments were for

  • Food & beverage$1,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,140 in reported general payments places this provider in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$36,672
Medicare patients
248
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$86,889
JardianceEmpagliflozin33$49,774
TrulicityDulaglutide19$36,393
MounjaroTirzepatide25$31,660
FarxigaDapagliflozin Propanediol23$22,263
Levothyroxine Sodium499$17,019
JanuviaSitagliptin Phosphate11$12,719
Tresiba Flextouch U-100Insulin Degludec13$10,407
HumalogInsulin Lispro26$9,218
Fiasp FlextouchInsulin Aspart (Niacinamide)21$9,137
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$8,790
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$7,226
Humalog Kwikpen U-100Insulin Lispro31$7,140
SynthroidLevothyroxine Sodium84$6,283
Testosterone23$6,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$307$86,88968 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$84$77,27170 claims
AstraZenecaFarxiga$17$22,26323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →